Growth Opportunities in Global Pharmaceutical Logistics

Growth Opportunities in Global Pharmaceutical Logistics

Cold chain Investments and Hybrid Clinical Trials to Ensure Transformational Growth of Pharmaceutical Logistics

RELEASE DATE
30-Dec-2022
REGION
Global
Research Code: MG72-01-00-00-00
SKU: HC03630-GL-MT_27380
AvailableYesPDF Download

$2,450.00

Special Price $2,205.00 save 10 %

In stock
SKU
HC03630-GL-MT_27380

$2,450.00

$2,205.00save 10 %

DownloadLink
ENQUIRE NOW

Description

Medicine production supply chains are currently operating under huge stress due to the war in Ukraine, COVID-19-related disruptions, logistics bottlenecks, and inflation. An energy-related shutdown of production would have a detrimental effect on the supply of critical medicines to patients in the EU and worldwide. The excessive amount of pressure on healthcare supply chains worldwide is driving companies to address vulnerabilities.
Pharmaceutical companies will need to rely heavily on an unprecedented level of cooperation from raw material suppliers, government agencies, and contract development and manufacturing organizations.

The increasing focus on biologics, adoption of technology, and shift to patient-centric model is transforming the pharma logistics market; the COVID-19 pandemic has sped up the rate of transformation and acted as a catalyst for the adoption of decentralized trials. This has increased the complexity of coordination of not only clinical trial supply management but also healthcare professionals, and arranging necessary infrastructure for drug storage and infusion.

This research analytics on the global pharmaceutical logistics market identifies some of the leading growth opportunity areas in cold chain capabilities for next-generation vaccines and biologics and hybrid trial logistics ensuring patient enrollment and diversity, highlighting the improved last-mile connectivity to propagate the anytime-anywhere care business model. In addition, the market is witnessing the simultaneous adoption of predictive supply chain solutions that optimize pharma operations and improve profitability.

Author: Unmesh Lal

Table of Contents

Why is it Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on the Pharmaceutical Logistics Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Scope of Analysis

Segmentation

Market Dynamics

Market Dynamics (continued)

Value Chain Analysis

Key Competitors

Vendor Landscape

Growth Drivers for Pharmaceutical Logistics

Growth Restraints for Pharmaceutical Logistics

Regional Analysis—North America (NA)

Regional Analysis—Europe

Regional Analysis—United Kingdom (UK)

Regional Analysis—Asia-Pacific (APAC)

Contract-logistics-provider-related Developments

Contract-logistics-provider-related Developments (continued)

Supply-chain-solution-provider-related Developments

Supply-chain-solution-provider-related Developments (continued)

CDMO-r

CDMO-r (continued)

CRO-related Developments

CRO-related Developments (continued)

Pharma LogisticsPrimed for Business Model Disruption

Growth Opportunity Universe—A Summary

Growth Opportunity Universe Summary

Growth Opportunity 1: Repurposing Cold Chain Capabilities

Growth Opportunity 1: Repurposing Cold Chain Capabilities (continued)

Global Cold-Chain Products Sales

Global Cold-Chain Products Sales (continued)

Global Cold-Chain Logistics Spending

Global Cold-Chain Logistics Spending

Growth Opportunity 2: Hybrid Trial Logistics

Growth Opportunity 2: Hybrid Trial Logistics (continued)

Case Study—DHL

Case Study—Marken (UPS)

Growth Opportunity 3: Improved Last-mile Connectivity

Growth Opportunity 3: Improved Last-mile Connectivity (continued)

eCommerce—Disrupting the Traditional Supply Chain Model

Case Study—Capsule

Growth Opportunity 4: Predictive Supply Chain

Growth Opportunity 4: Predictive Supply Chain (continued)

Case Study—Trek Therapeutics Uses Ambrosus’ Blockchain Solution for Quality Control

Case Study—Macro-Eyes’ ML Solutions Bring Predictability to the Vaccine Supply Chain

Companies to Action

List of Exhibits

Legal Disclaimer

Medicine production supply chains are currently operating under huge stress due to the war in Ukraine, COVID-19-related disruptions, logistics bottlenecks, and inflation. An energy-related shutdown of production would have a detrimental effect on the supply of critical medicines to patients in the EU and worldwide. The excessive amount of pressure on healthcare supply chains worldwide is driving companies to address vulnerabilities. Pharmaceutical companies will need to rely heavily on an unprecedented level of cooperation from raw material suppliers, government agencies, and contract development and manufacturing organizations. The increasing focus on biologics, adoption of technology, and shift to patient-centric model is transforming the pharma logistics market; the COVID-19 pandemic has sped up the rate of transformation and acted as a catalyst for the adoption of decentralized trials. This has increased the complexity of coordination of not only clinical trial supply management but also healthcare professionals, and arranging necessary infrastructure for drug storage and infusion. This research analytics on the global pharmaceutical logistics market identifies some of the leading growth opportunity areas in cold chain capabilities for next-generation vaccines and biologics and hybrid trial logistics ensuring patient enrollment and diversity, highlighting the improved last-mile connectivity to propagate the anytime-anywhere care business model. In addition, the market is witnessing the simultaneous adoption of predictive supply chain solutions that optimize pharma operations and improve profitability. Author: Unmesh Lal
More Information
Author Unmesh Lal
Industries Healthcare
No Index No
Is Prebook No
Podcast No
WIP Number MG72-01-00-00-00